lecture 3 kinases Flashcards

1
Q

what are kinase’s role?

A

catalyze transfer of phosphate groups
cell signaling is driven by transfer of phosphates
ATP is major source of phosphate
tyrosine, serine, threonine are used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the role of phosphatases?

A

balance activity of kinases by removing phosphates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the types of kinase inhibitors?

A

Type 1: bind to active conformation
Type 2: bind and stabilize the inactive conformation of kinase
Type 3: occupy an allosteric pocket outside the ATP-binding pocket

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

which drugs are EGFR targeted kinase inhibitors?

A

getfitinib
erlotinib
afatinib
osimertinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is gefiitinib?

A

EGFR targeted kinase inhibitor
approved NSCLC exon 19/20 mutations
T790M causes resistance to getfitinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is erlotinib?

A

reversible inhibitor EGFR
competitive inhibition by binding to ATP site
approved metastatic NSCLC exon 19/20 mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is afatinib?

A

covalent inhibitor of all ErbB receptors
approved for EGFR mutant NSCLC w/ EGFR mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is osimertinib?

A

covalent inhibitor for EGFR
approved for T790M

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the HER2 inhibitors?

A

lapatinib
tucantinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is lapatinib?

A

irreversibly blocks HER2 and EGFR
selective for HER2+ breast cancer, approved (in combo with capecitabine) for metastatic breast cancer
reversible decrease in cardiac function –> watch for sx CHF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is tucatinib?

A

selective treatment for HER2+ breast cancer
approved second line (combo with trastuzumab and capecitabine) for metastatic breast cancer
reduced sides compared to laptinib possibly bc of increased specificity to HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is FLT mutation cause?

A

FLT3 is responsible for hemapoeitic cell survival and proliferation
mutations cause acute myeloid luekemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the FLT3 inhibitors?

A

midostaurin - 1st gen
crenolanib - 2nd gen
quizartinib - type 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the philadelphia chromosome?

A

it is demonstrable in 95% of chronic myeloid leukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are drugs used for BCR-Abl translocations?

A

imantinib
ponatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is imantinib?

A

type 2 inhibitor of Abl tyrosine kinase
indicated for CML

17
Q

what is ponatinib?

A

BCR-Abl inhibitor
effective for all major forms of BCR-abl
can inhibit gatekeeper mutation T315I

18
Q

what is EML4-ALK a significant driver for?

A

lung cancer
ALK innapropriately fuses with EML4 –> and causes constituvely active

19
Q

what are ALK inhibitors?

A

alectinib

20
Q

what is alectinib?

A

ALK inhibitor
used for ALK+ metastatic NSCLC for intolerant to crizotinib

21
Q

BRAF mutations?

A

melanoma

22
Q

what is a BRAF inhibitor?

A

dabrafenib

23
Q

what is dabrafenib?

A

BRAF inhibitor
approved for metastatic melanoma
approved for NSCLC that are positive for BRAF+

24
Q

what is trametinib?

A

inhibits MEK1/2
approved for combo with BRAF inhibitor

25
Q

what is bruton’s tyrosine kinase malignancies?

A

BTK is responsible normal B cell activity
used in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia(CLL)

26
Q

what is a BTK inhibitor?

A

acalbrutinib

27
Q

what is acalabrutinib?

A

covalent BTK inhibitor
used for B-cell lymphoma

28
Q

what are mTOR inhibitors?

A

sirolimus - inhibits mTOR
everolimus - advanced renal carcinoma. only inhibiots mTORC1 not mTORC2